Contact Us
Drug Search Results
More Filters [+]

MK-0812

Alternative Names: mk-0812, mk0812, mk 0812
Latest Update: 2024-02-25
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CCL2 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for MK-0812

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Multiple Sclerosis, Relapsing-Remitting|Arthritis, Rheumatoid

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
MK0812-003

P2

Terminated

Multiple Sclerosis, Relapsing-Remitting

2005-12-01

MK0812-008

P2

Completed

Arthritis, Rheumatoid

2005-05-01

Recent News Events

Date

Type

Title

02/25/2024

PubMed

 Identification of effective CCR2 inhibitors for cancer therapy using humanized mice.

03/01/2020

PubMed

 In situ crystallography as an emerging method for structure solution of membrane proteins: the case of CCR2A.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions